Synthesis, in vivo rhesus monkey biodistribution and in vitro evaluation of a 11C-labelled potent aromatase inhibitor:: [N-methyl-11C]vorozole

被引:26
作者
Lidstrom, P
Bonasera, TA
Kirilovas, D
Lindblom, B
Lu, L
Bergstrom, E
Bergstrom, M
Westlin, JE
Langstrom, B [1 ]
机构
[1] Univ Uppsala, PET Ctr, UAS, S-75185 Uppsala, Sweden
[2] Univ Uppsala, Dept Organ Chem, S-75121 Uppsala, Sweden
[3] Dept Obstet & Gynaecol, S-75185 Uppsala, Sweden
[4] Uppsala Univ, Dept Oncol, UAS, S-75185 Uppsala, Sweden
关键词
aromatase; inhibitor; N-methyl-C-11]vorozole; biodistribution;
D O I
10.1016/S0969-8051(98)00009-2
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
[N-methyl-C-11]Vorozole, a high-affinity aromatase-binding radiotracer, was synthesized through N-methylation of the corresponding nor-vorozole derivative using [C-11]methyl iodide. [N-methyl-C-11]Vorozole was obtained in 53-56% radiochemical yield based on [C-11]methyl iodide within 40 min of the end of radionuclide production. The final formulation was >98% radiochemically pure and had a specific radioactivity of 10-143 GBq/mu mol. In vitro, [N-methyl-C-11]vorozole displayed high and specific binding to aromatase rich human placenta. [N-methyl-C-11]Vorozole binding to other tissues was lower and less specific. The dissociation constant measured was in the low nhl range (K(d )1.7 nM), consistent with published K-i values for vorozole. Biodistribution studies in rhesus monkeys showed high Liver uptake, which reached a constant level of 20% of the injected dose after 10 min, and an otherwise relatively even distribution of radioactivity. Pretreatment with vorozole only caused minor alterations of the biodistribution of the tracer. NUCL MED BIOL 25;5:497-501, 1998. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:497 / 501
页数:5
相关论文
共 19 条
  • [1] Bjurling P., 1995, P 6 INT WORKSHOP TAR, P282
  • [2] BRODIE A, 1994, DESIGN ENZYME INHIBI, V2, P414
  • [3] AROMATASE INHIBITORS IN THE TREATMENT OF BREAST-CANCER
    BRODIE, AMH
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1994, 49 (4-6) : 281 - 287
  • [4] AROMATASE INHIBITORS AND HORMONE-DEPENDENT CANCERS
    BRODIE, AMH
    BANKS, PK
    INKSTER, SE
    DOWSETT, M
    COOMBES, RC
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1990, 37 (03) : 327 - 333
  • [5] MECHANISM AND INHIBITION OF CYTOCHROME-P-450 AROMATASE
    COLE, PA
    ROBINSON, CH
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1990, 33 (11) : 2933 - 2942
  • [6] 4-HYDROXYANDROSTENEDIONE IN TREATMENT OF POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER
    COOMBES, RC
    GOSS, P
    DOWSETT, M
    GAZET, JC
    BRODIE, A
    [J]. LANCET, 1984, 2 (8414) : 1237 - 1239
  • [7] DECOSTER R, 1994, CLIN USE AROMATASE I, P173
  • [8] Dowsett M, 1995, CLIN CANCER RES, V1, P1511
  • [9] A COMPARISON OF THE ENDOCRINE EFFECTS OF LOW-DOSE AMINOGLUTETHIMIDE WITH AND WITHOUT HYDROCORTISONE IN POSTMENOPAUSAL BREAST-CANCER PATIENTS
    DOWSETT, M
    HARRIS, AL
    STUARTHARRIS, R
    HILL, M
    CANTWELL, BMJ
    SMITH, IE
    JEFFCOATE, SL
    [J]. BRITISH JOURNAL OF CANCER, 1985, 52 (04) : 525 - 529
  • [10] GOLLER L, 1995, ONCOL REP, V2, P717